Regenerative Medical Technology Group Inc.

Vertically integrated regenerative-medicine micro-cap with growing revenue but crushing debt service and severe liquidity distress.

Strengths

• High gross margin (55%, 92nd pct) and 24% revenue growth across training/products/procedures
• Diversified, partly recurring revenue model with real operations

Risks

• $7.4M interest expense produced a $7.8M net loss on $5.1M revenue; ROA -1.74 (7th pct)
• Current ratio 0.033 (8th pct) and ~2.9-quarter runway signal acute solvency risk
• Heavy reliance on convertible notes/derivatives; penny-stock, lender-call risk disclosed

Notable findings

• Net lossNet loss (net margin -153.2%)
• Cash burnNegative free cash flow (-1.3M)
• Weak liquidityCurrent ratio 0.03 (<1)
• Customer concentration~17% of revenue from one customer/distributor — 17 % Cost of revenue 2,289,537 1,284,375 1,005,162 78